Rebiotix Inc.
Quick facts
Phase 3 pipeline
- RBX2660 · Infectious Disease / Gastroenterology
RBX2660 is a microbiota restoration therapy that repopulates the gut microbiome to treat recurrent Clostridioides difficile infection. - Standard of Care Antibiotics · Infectious Diseases
Standard of care antibiotics work by inhibiting bacterial cell wall synthesis or interfering with protein synthesis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Rebiotix Inc.
What is Rebiotix Inc.'s pipeline?
Rebiotix Inc. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include RBX2660, Standard of Care Antibiotics.
Related
- Sector hub: All tracked pharma companies